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A Dominant Mutation in FBXO38 Causes
Distal Spinal Muscular Atrophy with Calf Predominance
Charlotte J. Sumner,1,2,* Constantin d’Ydewalle,1,3 Joe Wooley,1 Katherine A. Fawcett,4,5
Dena Hernandez,6 Alice R. Gardiner,4,5 Bernadett Kalmar,5 Robert H. Baloh,7 Michael Gonzalez,8
Stephan Zu¨chner,8 Horia C. Stanescu,9 Robert Kleta,9 Ami Mankodi,10 David R. Cornblath,1
Kevin B. Boylan,11 Mary M. Reilly,4,5 Linda Greensmith,5 Andrew B. Singleton,6 Matthew B. Harms,12
Alexander M. Rossor,5 and Henry Houlden4,5,*
Spinal muscular atrophies (SMAs) are a heterogeneous group of inherited disorders characterized by degeneration of anterior horn cells
and progressive muscle weakness. In two unrelated families affected by a distinct form of autosomal-dominant distal SMA initially man-
ifesting with calf weakness, we identified by genetic linkage analysis and exome sequencing a heterozygous missense mutation,
c.616T>C (p.Cys206Arg), in F-box protein 38 (FBXO38). FBXO38 is a known coactivator of the transcription factor Kru¨ppel-like factor
7 (KLF7), which regulates genes required for neuronal axon outgrowth and repair. The p.Cys206Arg substitution did not alter the sub-
cellular localization of FBXO38 but did impair KLF7-mediated transactivation of a KLF7-responsive promoter construct and endogenous
KLF7 target genes in both heterologously expressing human embryonic kidney 293T cells and fibroblasts derived from individuals with
the FBXO38 missense mutation. This transcriptional dysregulation was associated with an impairment of neurite outgrowth in
primary motor neurons. Together, these results suggest that a transcriptional regulatory pathway that has a well-established role
in axonal development could also be critical for neuronal maintenance and highlight the importance of FBXO38 and KLF7 activity
in motor neurons.Alpha motor neurons are very large cells with axons that
must extend as long as a meter in humans to reach their
muscle target. Their development depends on a series of
transcription factors that determine their initial specifica-
tion,1 as well as transcriptional programs that control
axonal outgrowth and path finding.2 Spinal muscular
atrophies (SMAs) result in the degeneration of these neu-
rons, leading to muscle wasting and weakness. These dis-
eases can be clinically classified to some extent on the basis
of age of onset, pattern of muscle involvement, and inher-
itance pattern.3 To date, mutations in approximately
15 genes have been associated with distal forms of SMA
(also known as distal hereditary motor neuropathy
[dHMN]), and they play roles in axonal transport, RNA
metabolism, and protein aggregation and ubiquitination,
among other functions.4 Nonetheless, the genetic basis
of most forms of SMA and HMN remains unknown.5
We examined subjects from two families affected
by distal SMA with calf predominance (Figures 1A and 1B
and Table 1); one of these families was previously re-
ported.6 All subjects were enrolled in protocols approved
by the institutional review boards at the National Institute
of Neurological Disorders and Stroke and University Col-
lege London Hospitals (99/N103) after providing informed1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, M
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in the calves and subsequent slowly progressive weakness
of both distal and proximal leg and arm muscles
(Figure 1C and Table 1). Particularly weak arm muscles
included the triceps and intrinsic hand muscles, such as
the abductor pollicis brevis and first dorsal interosseus
(Figure 1C). Ankle tendon reflexes were absent in 10 of
11 affected individuals tested. Age of onset ranged from
13 to 48 years, and clinical severity was variable from
mild weakness at age 73 years in individual III-11 in family
1 to a complete lack of ambulation in three individuals (III-
3 and IV-8 in family 1 and III-1 in family 2) aged 82, 45,
and 48 years, respectively (Table 1). The five individuals
with sensory loss on examination (Table 1) had other
possible explanations, including lumbar spondylosis and
diabetes. Nerve conduction studies in five individuals
(IV-3, IV-8, and V-4 in family 1 and III-1 and IV-1 in fam-
ily 2) showed reduced motor-evoked amplitudes in the
lower limbs in the three older individuals and normal sen-
sory conductions in all. These results are consistent with
previously reported nerve conduction studies in family 1
individuals, all of whom had normal sural nerve sensory
responses.6 Electromyography revealed chronic neuro-
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Figure 1. Genetic and Phenotypic Characteristics of Distal SMA with Calf Predominance
(A and B) Pedigrees of family 1 (A) and family 2 (B) show affected family members in multiple generations. Color coding is as follows:
white, unaffected; black, affected; and gray, unknown disease status. Underlining indicates that a DNA sample was collected.
(C) Calf weakness was the earliest symptom inmost individuals with the inability to stand on the toes and was evident in affected family
member V-4, but not in his unaffected brother, V-3. Triceps muscle weakness and wasting and involvement of intrinsic hand muscles
were evident later in the disease course, as demonstrated in two affected family members, IV-8 and IV-3. Arrows indicate weak, atrophied
muscles. Written consent was obtained for the publication of these photographs.
(D) Hematoxylin and eosin (H&E) staining (top row) and ATPase 9.4 staining (bottom row) of gastrocnemius muscle cross sections
demonstrate a small group of angular, atrophied myofibers in muscle from IV-2. The muscle biopsy from IV-8 shows more severe
myofiber atrophy and interstitial fibrosis. Myofibers of normal size are principally type II.
(E) Sequencing shows a heterozygous c.616T>C change in affected familymembers in both families, but not unaffected familymembers.
(F) The domain structure of FBXO38 indicates that the p.Cys206Arg amino acid substitution is near the second nuclear export signal
(NES) domain. The protein sequence in this region is highly conserved in other mammals. NLS ¼ nuclear localization signal.positive sharp waves, suggesting active denervation in four
of five affected individuals. Muscle biopsy of the gastrocne-
mius muscle (IV-2 and IV-8 in family 1) confirmed neuro-
genic changes of variable severity (Figure 1D).
Known mutations in genes associated with dHMN
were excluded by Sanger sequencing, and genetic linkage
analysis was carried out in family 1. This revealed one
candidate linkage region on chromosome 5 (LOD score
of 2.71) (Figure S1, available online). Exome sequencing
of four affected family members (III-3, IV-20, V-1, and
V-4) identified a heterozygous c.616T>C mutation in
F-box protein 38 (FBXO38 [MIM 608533], RefSeq accession
number NM_030793.4), located in the linked region on
chromosome 5. This was not present in the National Heart,
Lung, and Blood Institute Exome Sequencing ProjectThe AmericanExome Variant Server (EVS), the 1000 Genomes Project,
or over 582 internal normal control exome samples.
Sanger sequencing confirmed that this change segregated
with the disease in all affected individuals in family 1
and was not present in unaffected individuals (Figure 1E)
or in 392 ethnically matched controls. Three individuals
carried the mutation but were not available for detailed
clinical or electrophysiological examination for the deter-
mination of their disease status. Sanger and whole-exome
sequencing of a further 192 subjects with dHMN identified
the same c.616T>C mutation in FBXO38 in dHMN-
affected family 2 (Figures 1B and 1E). The affected
haplotype of this family was different than that of family
1, indicating that the two families are not from the same
founder. The c.616T>C mutation results in a p.Cys206ArgJournal of Human Genetics 93, 976–983, November 7, 2013 977
Table 1. Phenotypic Characteristics of Subjects with Distal SMA with Calf-Predominant Weakness
Individual
Age at Onset
(Years)
Age of Evaluation
(Years) First Symptom
Arm Weakness
Proximal Distal
Leg Weakness
Proximal Distal
Sensory
Loss Ambulatory
Family 1
III-3 25 82 difficulty standing on toes moderate severe moderate severe severe no
III-11 48 73 difficulty standing on toes none mild none moderate mild yes
IV-2 25 57 difficulty standing on toes mild mild mild mild none yes
IV-3 44 57 difficulty running mild mild mild severe none yes
IV-4 18 57 difficulty walking mild mild mild severe none yes
IV-8 17 45 difficulty running severe severe severe severe none no
IV-17 35 52 difficulty walking none none none mild mild yes
IV-20 42 47 difficulty standing on toes mild mild none mild ND yes
V-1 13 34 difficulty running none moderate none severe none yes
V-4 25 36 difficulty standing on toes none mild none moderate mild yes
V-5 22 calf fasiculations none none none none none yes
V-28 30 35 difficulty standing on toes none none none mild mild yes
Family 2
III-1 19 48 difficulty running moderate severe severe severe none no
IV-1 19 27 difficulty standing on toes mild mild mild severe none yes
The following abbreviation is used: ND, not determined.amino acid change in a conserved region of FBXO38
(Figure 1F).
In order to determine whether FBXO38 is expressed in
tissue types relevant to SMA pathogenesis, we performed
quantitative RT-PCR (qRT-PCR) for FBXO38 in a variety
of human tissues, including spinal cord and muscle, as
well as gene expression analysis in different regions of
the human brain (Figures S2A–S2C). As has been previ-
ously reported in mouse tissues,7 FBXO38 expression was
evident in both spinal cord and brain tissues. In contrast
to prior observations in mouse muscle, we also detected
FBXO38 in human skeletal-muscle tissue (Figures S2A
and S2B).
Because the p.Cys206Arg substitution is in close prox-
imity to the second nuclear export signal (NES) of
FBXO38 (Figure 1F), we investigated whether this altered
its subcellular localization. Human embryonic kidney
293T (HEK293T) cells were transfected with FBXO38WT
-FLAG or FBXO38p.Cys206Arg -FLAG plasmids (Figures 2A
and 2B). Both wild-type (WT) and altered FBXO38 were
localized in the nucleus and cytoplasm, as detected by
immunofluorescence (Figure 2A), and subcellular fraction-
ation showed equal amounts of WTand altered FBXO38 in
these compartments (Figure 2B). In order to examine sub-
cellular localization in a neuronal cell line, we infected
differentiated SH-SY5Y cells with FBXO38-V5 lentivirus
and examined the ratio of nuclear to cytoplasmic fluores-
cence intensity (Figure 2C). In these cells, FBXO38
appeared to be preferentially accumulated in the nucleus,
but there was no difference between cells transfected978 The American Journal of Human Genetics 93, 976–983, Novembwith WT FBXO38 and those transfected with altered
FBXO38 (Figure 2D).
FBXO38 is a member of the F-box family of proteins,
which contain an F-box motif in the amino terminus.8
The most well-described function of many of the F-box
proteins is to act as a subunit of the SCF (Skp1-cullin-F-
box) E3 ubiquitin ligase complex.9–11 E3 ubiquitin ligases
assist in the attachment of ubiquitin chains to target pro-
teins, and the protein recognition sites of F-box proteins
are believed to mediate the specificity of target proteins.
Mutations in two genes encoding E3 ubiquitin ligases
(LRSAM1 [MIM 610933] and HSJ1 [MIM 604139]) have
been described in autosomal-dominant and -recessive
Charcot-Marie-Tooth disease.12–15 In order to examine
whether the p.Cys206Arg substitution in FBXO38 mod-
ulates the ability of FBXO38 and the SCF complex to
ubiquitinate target proteins, we transfected HEK293T
cells with FBXO38WT-FLAG and FBXO38C206R-FLAG with
or without the proteasome inhibitor MG-132 and exam-
ined protein ubiquitination patterns by immunoblot. No
differences were seen between cells transfected with
WT FBXO38 and those transfected with altered FBXO38
(Figure S3).
In addition to playing roles in ubiquitination, F-box
proteins might also function as transcription factors.16
FBXO38 in particular is a coactivator of Kru¨ppel-like factor
7 (KLF7),7,17 a member of the KLF family of zinc finger
transcription factors.18 Like FBXO38, KLF7 is widely
expressed in the developing nervous system, including
in motor neurons.7,19 KLF7 plays critical roles in axonaler 7, 2013
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Figure 2. The p.Cys206Arg Substitution Does Not Alter Subcellular Localization of FBXO38
(A) BothWTand altered FBXO38 (red) were localized in the cytoplasm and nucleus (blue) of HEK293Tcells transfected with FBXO38WT-
FLAG- and FBXO38p.Cys206Arg-FLAG-tagged constructs and were detected with anti-FLAG at 24 hr. The scale bar represents 10 mm.
(B) Representative immunoblot analysis of nuclear and cytoplasmic protein fractions isolated from HEK293T cells transfected with
FBXO38WT-FLAG or FBXO38 p.Cys206Arg -FLAG. Themembrane was reprobed for a-tubulin and histone deacetylase 1 (HDAC1) for confir-
mation of fractionation and equal loading.
(C) Quantification of the fraction of FBXO38 in nuclear versus cytoplasmic compartments (n ¼ 3 independent transfections,
mean5 SEM).
(D) Differentiated SH-SY5Y cells were infected with V5-tagged FBXO38WT- or FBXO38p.Cys206Arg-expressing lentivirus, and FBXO38 was
detected after 14 days with anti-V5 (green) in the cytoplasm (MAP2) and nucleus (DAPI). The scale bar represents 20 mm.
(E) The ratio of nuclear to cytoplasmic FBXO38 fluorescence signal intensity expressed in arbitrary units (AU) was equivalent in SH-SY5Y
cells expressing FBXO38WT and FBXO38p.Cys206Arg (FBXO38WT, n ¼ 6 coverslips, 106 cells, mean ratio 5 SEM ¼ 3.48 5 0.3;
FBXO38p.Cys206Arg, n ¼ 6 coverslips, 95 cells, mean ratio5 SEM ¼ 3.235 0.26).outgrowth and regeneration20,21 by activating the expres-
sion of such genes as growth-associated protein 43
(GAP43 [MIM 162060]), neurotrophic tyrosine kinase
receptor type 1 (NTRK1, also known as TRKA [MIM
191315]), neurotrophic tyrosine kinase receptor 2
(NTRK2, also known as TRKB [MIM 600456]), cyclin-
dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A
[MIM 116899]), and L1 cell adhesion molecule (L1CAM
[MIM 308840]).7,22–24 In order to examine the transcrip-
tional activity of FBXO38 and KLF7, we transfected
HEK293T cells with a reporter construct containing the
KLF7-responsive CDKN1A promoter fused to luciferase7
together with FBXO38WT-FLAG or FBXO38p.Cys206Arg-
FLAG with or without KLF7-Myc (Figure 3A). We verified
that total protein levels (Figure 3B) and subcellular distri-
bution (Figure S4) of FBXO38 were unchanged by exoge-
nous KLF7. Similarly, KLF7 levels were equivalent in cells
cotransfected with WT or altered FBXO38 (Figure 3B and
Figure S4). FBXO38 alone showed minimal ability to acti-
vate the CDKN1A promoter, whereas KLF7 alone doubled
promoter activity. In the presence of both KLF7 and WT
FBXO38, promoter activity was increased by approxi-The Americanmately 8-fold, but this synergy was completely lost in
the presence of altered FBXO38 (Figure 3C). The expres-
sion level of endogenous KLF7 target genes, including
CDKN1A, NTRK1, and L1CAM, was also examined by
qRT-PCR in transfected HEK293T cells, and in the presence
of exogenous KLF7, each showed activation that was
impaired by altered FBXO38 (Figure 3D).
In order to determine whether similar patterns would be
observed when FBXO38 was expressed under endogenous
conditions, we examined fibroblast cell lines isolated from
three affected and three unaffected individuals in family 1.
These cells expressed equivalent levels of endogenous
FBXO38 transcript and FBXO38 (Figure S5), but KLF7-
induced CDKN1A-promoter activation was significantly
impaired in cells with mutant FBXO38 (Figure 3E).
Although NTRK1 expression could not be detected
in these cells, endogenous expression of CDKN1A and
L1CAM was also impaired in mutant cells. Interestingly,
CDKN1A expression was impaired both in the absence
and in the presence of exogenous KLF7, whereas L1CAM
expression was impaired only in the presence of KLF7.
Together, these data indicate that the p.Cys206ArgJournal of Human Genetics 93, 976–983, November 7, 2013 979
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Figure 3. Altered FBXO38 Impairs Activation of KLF7 Target Genes
(A) Schematic representation of the putative transcriptional functions of KLF7 and FBXO38. KLF7 recognizes a consensus motif within
the promoter of KLF7 target genes, such as CDKN1A, NTRK1, and L1CAM. FBXO38 might act as a transcriptional coactivator.
(B) Representative immunoblot analysis of HEK293T cells transfected with FBXO38WT-FLAG or FBXO38p.Cys206Arg-FLAG and empty
vector (–KLF7) or KLF7-cMyc (þKLF7). The membrane was reprobed for GAPDH for confirmation of equal loading.
(C) HEK293T cells were cotransfected with FBXO38WT-FLAG or FBXO38 p.Cys206Arg -FLAG, empty vector (–KLF7) or KLF7-cMyc (þKLF7),
firefly luciferase reporter driven by the CDKN1A promoter, and the renilla luciferase reporter driven by the cytomegalovirus (CMV) pro-
moter. The CDKN1A-promoter activity in HEK293Tcells was expressed relative to the CMV reporter in relative luminescence units (RLU)
and scaled to mock-transfected cells.
(D) HEK293T cells were cotransfected with FBXO38WT-FLAG or FBXO38p.Cys206Arg-FLAG and with empty vector (–KLF7) or KLF7-cMyc
(þKLF7). Transcript levels of CDKN1A (left panel), NTRK1 (middle panel), and L1CAM (right panel) were determined by qRT-PCR. Tran-
script levels were normalized to B2M (MIM 109700) and GAPDH (MIM 138400) (in normalized relative quantities [NRQ]) and scaled to
mock-transfected cells.
(E) WT fibroblasts derived from unaffected individuals (V-2, V-3 and V-29 from family 1) and p.Cys206Arg fibroblasts derived from
affected individuals (IV-8, IV-17 and V-4 from family 1) were cotransfected withCDKN1A firefly luciferase reporter and CMVrenilla lucif-
erase reporter and with empty vector (–KLF7) or KLF7-cMyc (þKLF7). TheCDKN1A-promoter activity in fibroblasts was expressed in RLU
and scaled to the RLU of one of the WT fibroblasts.
(F) Fibroblasts were transfected with empty vector or KLF7-cMyc (þKLF7). Transcript levels of CDKN1A (left panel) and L1CAM (right
panel) were determined by qRT-PCR. Transcript levels were normalized to B2M and EIF4A2 (MIM 601102) levels (in NRQ) and scaled
to one of the WT fibroblasts.
In (C)–(F), n ¼ 3 independent transfections (mean 5 SEM), and a one-way ANOVA was performed with Tukey’s honest significant
difference (HSD) post hoc test. **p < 0.01, ***p < 0.001, ****p < 0.0001.substitution in FBXO38 causes impaired activation of
KLF7 target genes.
To investigate whether this disruption of transcrip-
tional activity resulted in an abnormality of motor
neuron morphology, we evaluated neurite outgrowth in980 The American Journal of Human Genetics 93, 976–983, Novembprimary motor neurons infected with FBXO38WT,
FBXO38p.Cys206Arg, and GFP-lentivirus (Figure 4A). Primary
motor neurons were infected separately with each of the
three lentiviruses, stained for the neuronal marker bIII
tubulin, and imaged in a blind fashion. The length ofer 7, 2013
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Figure 4. Altered FBXO38 Fails to Stimulate Neurite Outgrowth
(A) Mouse primary motor neurons were infected after 4 hr with
GFP-, FBXO38WT-, or FBXO38 p.Cys206Arg-expressing lentivirus con-
structs and fixed at 3 days. FBXO38was evident in the nucleus and
at low levels in the cytoplasm.
(B) An example of primary motor neuron shows the typical
appearance of neurites. An asterisk highlights the primary neurite.
(C) The average length of the primary neurite was determined.
Four coverslips were separately infected with virus, and 25 motor
neurons were analyzed per well (i.e., 100 motor neurons per con-
dition, n ¼ 4). *p < 0.05, **p < 0.01.
(D) The number of neurites per cell (mean5 SEM).each neurite (detected by bIII-tubulin-positive antibody
staining) from each infected motor neuron (detected by
V5-positive antibody staining) was then tracked manually
with MetaMorph analysis software. Small bIII-tubulin-pos-
itive cells with bipolar neurites were excluded because they
were likely to represent interneurons. FBXO38 localiza-
tion was evident primarily in the nucleus of these cells
(Figure 4A), andqRT-PCR confirmed equal expression levelsThe Americanof WT and mutant FBXO38-V5 transcript (WT FBXO38:
1.005 0.1 [SEM]; mutant FBXO38: 0.855 0.31; p ¼ 0.7).
Interestingly, exogenous FBXO38 was present at low levels
in primary motor neurons. Similar observations have been
made for KLF721 and imply that both proteins are under
tight regulatory control inneurons. In thosemotorneurons
showing FBXO38 immunofluorescence (Figure 4A), we
examined themean length of the longest (primary) neurite
(Figure 4B), as has been previously described.25 This was
higher in FBXO38WT-infected neurons (173 5 11.8 mm)
than in GFP-infected cells (75.9 5 12.6 mm) (p ¼ 0.008),
but neurite growth was suppressed in FBXO38p.Cys206Arg -
infected cells (134512.6mm) (p¼0.021) (Figure 4C). There
were no significant differences in the number of neurites
between FBXO38WT-infected and FBXO38 p.Cys206Arg -
infected cells (Figure4C)or in the average secondaryneurite
length between FBXO38WT-infected (54 5 2.9 mm),
FBXO38p.Cys206Arg-infected (45 5 8.7 mm) (p ¼ 0.3), or
GFP-infected (41.75 9.91 mm) (p¼ 0.317) motor neurons.
These results are in keeping with previous studies exam-
ining neurite outgrowth in neurons overexpressing KLF7;
in those studies, the greatest effect was seen in the longest
neurite.20
Together, our studies indicate that a dominant mutation
in FBXO38 causes distal SMAwith calf predominance. This
is an adult-onset, progressive SMAwith a muscle-weakness
pattern that is unusual, indicating vulnerability of specific
motor neuron populations. Such selectivity has been previ-
ously described for the thenar, quadriceps, and vocal focal
muscles in distal SMAs caused by mutations in GARS (MIM
600287),26 DYNC1H1 (MIM 600112),27 and TRPV4 (MIM
605427),28 respectively. It is possible that some individuals
with mutant FBXO38 develop sensory nerve involvement
late in the disease course, as has been observed in individ-
uals with other dHMNs, including those due to mutant
HSPB14,5 (MIM 602195), although it is mild compared to
the motor involvement.
FBXO38, also known as modulator of KLF7 activity
(MOKA), was first identified during a yeast two-hybrid
assay performed to identify interacting partners of the
transcription factor KLF7.7 Indeed, as demonstrated in
previous studies, our data confirm that WT FBXO38 is
a transcriptional coactivator of KLF7. In contrast, the
p.Cys206Arg change in FBXO38markedly impairs the acti-
vation of KLF7 target genes, and this is associated with
impaired growth of the primary neurite in primary motor
neurons. These deficits might be primarily due to a loss
of function of altered FBXO38 (haploinsufficiency); how-
ever, a dominant-negative effect might also be at work
given that some genes showed maximal gene activation
with exogenous KLF7 alone but showed repression with
the addition of mutant FBXO38. In addition, a gain-of-
function mechanism cannot be completely excluded
without a definition of the effects of FBXO38WT silencing.
Further studies will also be needed for determining
how the p.Cys206Arg substitution impairs KLF7 func-
tion. Possible mechanisms include an interruption ofJournal of Human Genetics 93, 976–983, November 7, 2013 981
direct or indirect protein interactions between FBXO38
and KLF7, abnormal recruitment of altered FBXO38 to
gene promoters, and/or impaired transactivation of target
genes.
KLF7 has a well-established role in neuronal develop-
ment, particularly of retinal ganglion and sensory neu-
rons.20,22,29,30 Recently, KLF7 has also been shown to
enhance corticospinal neuron regeneration in vivo after
spinal cord injury.21 Although KLF7 has not been previ-
ously studied in detail in alpha motor neurons, it is pre-
sent at high levels in these cells during development.7,19
Degeneration of motor neurons in individuals with altered
FBXO38 might occur as a result of impaired activation of a
regenerative transcriptional program in response to physi-
ological wear and tear on the motor nerve during aging.
Alternatively, it is possible that degeneration occurs as a
late consequence of an initial developmental disorder of
motor neurons. One of the genes that showed the most
significant expression change in cells in the presence of
altered FBXO38 was L1CAM. L1CAM is a member of the
immunoglobulin superfamily of adhesion molecules and
can bind to itself or other adhesion molecules to mediate
neurite outgrowth31,32 or nerve regeneration.33 Interest-
ingly, a mutation in L1CAM has been shown to cause
a form of X-linked hereditary spastic paraparesis (HSP,
MASA syndrome [MIM 303350]),34 illustrating the increas-
ingly recognized shared molecular mechanisms underly-
ing inherited neuropathies and HSPs.35Supplemental Data
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